HC Wainwright & Co. Maintains Buy on IGM Biosciences, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on IGM Biosciences (NASDAQ:IGMS) but has reduced the price target from $17 to $11.
November 15, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
IGM Biosciences' Buy rating is maintained by HC Wainwright & Co., but the price target is lowered from $17 to $11, indicating potential downside according to the analyst.
The reduction in price target by HC Wainwright & Co. suggests that the analyst sees less upside potential for IGM Biosciences, which could lead to a negative perception among investors and a potential short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100